Unicycive Therapeutics, Inc.
UNCY
$0.6379
$0.0081.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 143.33% | 91.01% | 24.94% | 23.26% | 29.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.20% | 46.70% | 5.27% | 71.24% | 88.72% |
| Operating Income | 13.20% | -46.70% | -5.27% | -71.24% | -119.04% |
| Income Before Tax | 102.72% | -176.03% | 5.47% | 356.77% | -43.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 102.72% | -176.03% | 5.47% | 356.77% | -43.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.72% | -176.03% | 5.47% | 356.77% | -43.83% |
| EBIT | 13.20% | -46.70% | -5.27% | -71.24% | -119.04% |
| EBITDA | 13.20% | -46.66% | -5.21% | -71.32% | -118.93% |
| EPS Basic | 100.73% | 8.99% | 65.85% | 127.55% | 37.45% |
| Normalized Basic EPS | 100.80% | 8.94% | 65.30% | 203.17% | 37.24% |
| EPS Diluted | 91.77% | 8.99% | 65.85% | 49.78% | 37.07% |
| Normalized Diluted EPS | 100.77% | 8.94% | 65.30% | 141.59% | 37.24% |
| Average Basic Shares Outstanding | 234.60% | 203.30% | 172.56% | 148.87% | 129.20% |
| Average Diluted Shares Outstanding | 254.70% | 203.30% | 172.56% | 517.36% | 129.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |